KCG
IMUC

Knight Capital Group’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Knight Capital Group’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q2 		$31K Buy
+398
New +$38.1K ﹤0.01% 3128

Other funds holding IMUC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Knight Capital Group's IMUC Position: Q2 2013 in Review

Knight Capital Group opened a new position in ImmunoCellular Therapeutics, Ltd. (IMUC) in Q2 2013: 398 shares worth $31K. The stake represents ﹤0.01% of the portfolio and ranks #3128 among its holdings.

49 funds tracked by Wall St. Rank hold IMUC as of Q2 2013.

  • Knight Capital Group held 398 shares of ImmunoCellular Therapeutics, Ltd. worth $31K as of Q2 2013.
  • ImmunoCellular Therapeutics, Ltd. was a new Knight Capital Group position in Q2 2013.
  • ImmunoCellular Therapeutics, Ltd. made up ﹤0.01% of Knight Capital Group's portfolio in Q2 2013, its #3128 holding.
  • 49 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q2 2013.

Based on Knight Capital Group's 13F filing for Q2 2013, filed 8 Aug 2013.